Atlas Signals

Ticker

Price

DCA

Rating

Live

14D

30D

45D

60D

90D

180D

GEHC

GE Healthcare Technologies

$88.21

$87.40

BUY

$87.52+2.1%

$85.40−0.3%

$82.15−4.1%

—

EVTC

Evertec Inc.

$32.83

$32.18

BUY

$33.10+0.8%

$32.95+0.4%

$31.80−3.1%

$33.20+1.1%

—

LIF

Life Storage Inc.

$16.18

$14.92

BUY

BUY→HOLD

$16.40+1.4%

$16.05−0.8%

—

CNQ

Canadian Natural Resources

$74.20

—

HOLD

$73.90−0.4%

$74.10−0.1%

$72.30−2.6%

$71.40−3.8%

$70.80−4.6%

—

ADP

Automatic Data Processing

$258.10

—

HOLD

$258.85+0.3%

$261.20+1.2%

$254.40−1.4%

$258.10+0.0%

$260.50+0.9%

$265.80+3.0%

—

NVDA

NVIDIA Corporation

$638.20

$612.00

HOLD

$649.70+1.8%

$640.10+0.3%

$625.00−2.1%

$610.40−4.4%

—

DMLP

Dorchester Minerals LP

$31.50

—

SELL

$30.95−1.8%

$30.40−3.5%

$29.10−7.6%

$28.20−10.5%

$27.85−11.6%

$27.50−12.7%

$26.90−14.6%

GEHC

GE HealthCare Technologies · Healthcare · Medical Devices

$88.21

+$0.81 today · +2.1%

OriginalBUYLiveBUY

TL;DR · Full analysis

BUY. GE HealthCare is a quality compounder in medical imaging with a durable competitive advantage, double-digit ROE and stable free cash flow. Fair entry valuation versus peers, and the recent analyst upgrade adds a near-term catalyst.

Company profile

GE HealthCare is a global leader in medical imaging and diagnostics, founded in 1994 as part of General Electric and spun off in 2023. The company operates four segments: Imaging, Ultrasound, Patient Care Solutions and Pharmaceutical Diagnostics. With more than 51,000 employees worldwide, GEHC serves hospitals, clinics and health systems in 160+ countries.

Fundamentals

ROE 18.2%: consistently above the sector average of 12%, indicating effective capital allocation
Free Cash Flow $2.1B: healthy cash generation supports debt reduction and buybacks
Operating margin 17.4%: stable profitability in a capital-intensive industry
D/E ratio 0.42: well-managed leverage following the spin-off from GE
Revenue growth YoY 6.8%: above average for a mature medtech market

Valuation

P/E 22.4: reasonable versus sector median 25.8 for medical devices
DCF fair value $108: +24% upside versus current price $87.40
Analyst target median $98: +12% upside, with 18 of 24 analysts at Buy/Outperform
EV/EBITDA 14.2: attractive versus the historical average of 16-18

Catalysts & theme

Recent analyst upgrade by Morgan Stanley to Overweight (target raised to $105) and a strong Q1 report with beats on both revenue and EPS. The sector benefits from ageing demographics and rising demand for diagnostic imaging. The quality screener flagged GEHC as top decile on the ROE + FCF margin combination.

Risks

Hospital capex cycle: vulnerable to delays in healthcare budgets
FX exposure: ~55% of revenue outside the US, sensitive to dollar strength
Reimbursement risk: Medicare/Medicaid pricing pressure could weigh on margins
Supply chain: dependency on rare earth metals for imaging equipment

Conclusion

GE HealthCare combines defensive sector characteristics with growth potential from AI-driven imaging. Fair entry valuation, strong balance sheet and a concrete near-term catalyst make it a quality compounder with asymmetric upside.

Why Atlas is watching this

Conviction 82 · BUY

GEHC surfaced because it clears Atlas's quality + value screen on every gate and just picked up a fresh near-term catalyst. It sits in the top decile on the ROE × free-cash-flow combination while still trading below the medical-devices sector multiple.

Quality screen passed

ROE 18.2% vs sector average 12%

Top decile

Valuation gate passed

P/E 22.4 vs sector median 25.8 · DCF +24%

Undervalued

Catalyst trigger

Morgan Stanley upgrade to Overweight · target $105

2 days ago

Insider buying

CFO + 2 directors bought on the open market · $2.1M (90d)

High conviction

Structural theme

Ageing demographics · rising diagnostic imaging demand

Tailwind

What changed

Last 30 days

2 days ago

Conviction raised 78 → 82

Verdict reaffirmed BUY after the analyst upgrade and Q1 beat strengthened the catalyst case.

3 days ago

Analyst target raised $98 → $105

Morgan Stanley moved to Overweight; 18 of 24 analysts now at Buy/Outperform.

1 week ago

FY guidance lifted after Q1 beat

Revenue and EPS both ahead of consensus; imaging segment drove the upgrade.

3 weeks ago

DCF fair value nudged $104 → $108

Lower assumed WACC after debt reduction from spin-off deleveraging.

Ask Atlas

Key metrics

ROE

18.2%

P/E

22.4

DCF Upside

+24%

FCF

$2.1B

Analyst

+12%

Conviction

News & events

Upcoming events

Jul

Q2 FY2026 earnings release

Earnings Before market open · consensus EPS $1.18

Aug

Quarterly dividend ex-date

Dividend $0.03 per share · yield 0.14%

Sep

Morgan Stanley Global Healthcare Conference

Conference Management fireside · 14:30 ET

Data quality

Coverage score

94%

Fundamentals synced 2h ago

SEC EDGAR filingsFMP 2hBloomberg 2hReuters 1dCompany IR 5dAnalyst consensus 1d

Track record

Since Q1 2024

Signals closed4

Hit rate75%

Avg. return vs entry+9.4%

Recent calls

Mar '25BUY+12.4%

Dec '24HOLD+4.1%

Sep '24BUY+18.2%

Jun '24BUY−3.0%

Every call counts in the track record — including the misses. View track record